Jonathan Todd Garland - 03 Mar 2023 Form 4 Insider Report for Cytek Biosciences, Inc. (CTKB)

Role
Chief Commercial Officer
Signature
/s/ Valerie Barnett, Attorney-in-Fact for Todd Garland
Issuer symbol
CTKB
Transactions as of
03 Mar 2023
Net transactions value
$0
Form type
4
Filing time
07 Mar 2023, 18:45:39 UTC
Previous filing
27 Apr 2022
Next filing
19 May 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTKB Employee Stock Option (right to buy) Award $0 +66,773 $0.000000 66,773 03 Mar 2023 Common Stock 66,773 $10.61 Direct F1
transaction CTKB Restricted Stock Units Award $0 +44,180 $0.000000 44,180 03 Mar 2023 Common Stock 44,180 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the shares subject to the option shall vest monthly over four years from the vesting commencement date of March 3, 2023. The option becomes fully vested on March 3, 2027.
F2 Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F3 The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested.